The IV drip that bills you later: the hidden methylation cost of NAD+ therapy

An IV drip feels like the fastest way to boost NAD+. It bypasses digestion, skips the gut, and lands straight in your bloodstream. But your body still sends you a bill afterward — and it's paid in a currency most people never hear about.

What NAD+ IV therapy is trying to do

NAD+ (nicotinamide adenine dinucleotide) is a molecule every cell in your body depends on for energy production, DNA repair, and the activity of a group of proteins called sirtuins, which help regulate aging and cellular stress. Levels of NAD+ decline with age, which is the main reason IV clinics market NAD+ infusions as an anti-aging, energy-boosting, and recovery treatment.

The logic is simple on the surface: NAD+ runs low, so put more of it directly into the blood. But NAD+ is a large, fragile molecule, and getting it into a cell intact is a much bigger challenge than getting it into a vein. What happens after the infusion is where the real story starts.

Step one: most of it never makes it into a cell

The moment NAD+ enters the bloodstream, it runs into an enzyme called CD38, found on the surface of cells throughout the body. CD38 is, by a wide margin, the most active NAD+-consuming enzyme in human tissue — some estimates suggest it accounts for the vast majority of extracellular NAD+ breakdown. It tears the NAD+ molecule apart almost as fast as it arrives, well before most of it can be absorbed intact into a cell.

This isn't a flaw unique to IV therapy — it's simply how the body has always handled NAD+ in the bloodstream. But it means a large share of an infused dose is broken down within minutes, not gently absorbed over hours.

Step two: the leftover pieces create a bottleneck

When CD38 breaks NAD+ apart, one of the fragments it releases is free nicotinamide. To be useful again, that nicotinamide has to be rebuilt back into NAD+, and that job belongs almost entirely to a single enzyme called NAMPT (nicotinamide phosphoribosyltransferase). NAMPT is widely described as the rate-limiting step of NAD+ regeneration, meaning it can only process nicotinamide at a fixed maximum speed, no matter how much is waiting in line.

A large IV dose can release nicotinamide faster than NAMPT is able to recycle it. The result is a backlog: more nicotinamide sitting around than the recycling system can immediately handle.

Step three: unprocessed nicotinamide isn't neutral

This is the part that's easy to miss. Leftover nicotinamide doesn't just sit quietly waiting its turn — it actively interferes with the very systems NAD+ is supposed to support. Research on sirtuins (the enzymes tied to NAD+'s anti-aging reputation) shows that nicotinamide is a direct feedback inhibitor: when it builds up, it binds back onto the sirtuin enzyme and slows it down. Nicotinamide has a similar suppressive relationship with PARP enzymes, which are involved in DNA repair. In short, a nicotinamide backlog can end up blunting the same pathways the infusion was meant to activate.

To prevent this pile-up from causing more disruption, the body calls on a second enzyme system to clear the excess.

Step four: clearing the backlog isn't free

The enzyme responsible for mopping up excess nicotinamide is called NNMT (nicotinamide N-methyltransferase). NNMT attaches a methyl group to nicotinamide, converting it into a compound called 1-methylnicotinamide, which is then cleared from the body. This reaction works, but it isn't free: every single methylation requires borrowing a methyl group from SAM (S-adenosylmethionine), the same universal methyl donor the body relies on for DNA repair, hormone clearance, and the production of mood-related brain chemicals like serotonin, dopamine, and norepinephrine.

Every time NNMT uses SAM to clear nicotinamide, SAM is converted into SAH (S-adenosylhomocysteine), which is then broken down into homocysteine. Push a large amount of nicotinamide through this pathway repeatedly, and you're asking the body to spend its limited methyl-group reserves on cleanup duty, rather than on its many other jobs.

Why IV delivery can make this heavier than an oral dose

Oral NAD+ precursors pass through digestion and the liver before reaching general circulation, a process known as first-pass metabolism, which naturally spreads out and moderates how much reaches the bloodstream at once. Oral bioavailability for NAD+ and its precursors is typically reported in the range of roughly 2 to 10%.

IV administration skips this filtering step entirely. It delivers the compound directly into circulation, and bioavailability is correspondingly far higher, with some comparisons reporting peak blood levels several times higher than an equivalent oral dose. That's the appeal of IV therapy — but it's also why the downstream nicotinamide surge, and the methylation demand that follows it, can be considerably larger and more concentrated in a single session than the same total amount taken orally over time.

Want to understand NAD+ better?

Aleksandra Duba explores NAD+, how cells use it, and the importance of managing NAD+ levels consciously in her book “You're Not Tired. You're Depleted.”

Learn more about the e-book →

The marker that can catch this early

Because this entire process runs through the methionine cycle, it leaves a trace that can actually be measured: homocysteine. Animal studies on high-dose nicotinamide and niacin intake have found measurable increases in homocysteine alongside drops in methyl-donor reserves such as betaine, and reductions in vitamin B6 and B12, both of which are needed to safely process homocysteine.

This doesn't mean everyone who receives a NAD+ IV infusion will see their homocysteine rise. It means that repeated high-dose infusions place real, measurable demand on the same methylation system that homocysteine reflects — and that demand is worth tracking if infusions are frequent or high-dose, rather than assumed to be consequence-free.

The bottom line

NAD+ IV therapy genuinely delivers more NAD+ into the bloodstream than an oral dose can — that part is well supported. But more delivered is not the same as more used well. A portion of every high-dose infusion gets converted into nicotinamide, some of that nicotinamide has to be cleared through a reaction that spends the body's SAM reserves, and that spending shows up, measurably, as homocysteine. None of this makes NAD+ IV therapy unsafe by default, but it does mean the dose and frequency matter, and that pairing regular infusions with methyl-donor support — vitamin B12, folate, and TMG (trimethylglycine) are the ones most directly involved — is a reasonable, evidence-based precaution rather than an unnecessary extra step. Checking homocysteine periodically is a simple, direct way to see whether that balance is being maintained.

Bibliography

1. The Multi-faceted Ecto-enzyme CD38: Roles in Immunomodulation, Cancer, Aging, and Metabolic Diseases. PubMed, PMID 31214171.
   https://pubmed.ncbi.nlm.nih.gov/31214171/
2. Mechanism of Inhibition of the Human Sirtuin Enzyme SIRT3 by Nicotinamide: Computational and Experimental Studies. PMC.
   https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164625/
3. Nicotinamide N-Methyltransferase Interacts with Enzymes of the Methionine Cycle and Regulates Methyl Donor Metabolism. PubMed, PMID 30226369.
   https://pubmed.ncbi.nlm.nih.gov/30226369/
4. From Rate-Limiting Enzyme to Therapeutic Target: The Promise of NAMPT in Neurodegenerative Diseases. PMC.
   https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322656/
5. Niacin (nicotinic acid) in non-physiological doses causes hyperhomocysteinaemia in Sprague-Dawley rats. British Journal of Nutrition, Cambridge Core.
   https://www.cambridge.org/core/services/aop-cambridge-core/content/view/9D8721450B89BCFAE4AB234C7A70EF17/S0007114502000363a.pdf/niacin_nicotinic_acid_in_nonphysiological_doses_causes_hyperhomocysteineaemia_in_spraguedawley_rats.pdf

Disclaimer: This content is provided for general educational purposes only and does not constitute medical advice, diagnosis, or treatment. It is not intended to replace consultation with a qualified physician or healthcare provider. Always consult a healthcare professional before starting, stopping, or combining any supplement, medication, IV therapy, or dietary compound.